F-star Therapeutics, Inc.: F-star Therapeutics Presents a No

Unique Structure and Tetravalency of FS118 Is Required to Modulate LAG-3 Cell Surface ExpressionCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 08, 2022(NASDAQ: FSTX), a clinical-stage biopharmaceutical

Related Keywords

Louisiana , United States , New Orleans , Cambridge , Cambridgeshire , United Kingdom , American , Helen Shik , Lindsey Trickett , John Fraunces , American Association For Cancer Research , Lifesci Advisors , Therapeutics Inc , Vp Investor Relations Communications , Shik Communications , Securities Exchange , Nasdaq , Unique Structure , American Association , Cancer Research , Annual Meeting , Neil Brewis , Chief Scientific Officer , Therapeutic Antibodies , Poster Section , F Star Therapeutics , Securities Exchange Act , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Quarterly Reports , Star , Herapeutics , Presents , Novel , Reduction , Shedding , Mechanism , Fs118 , Racr , 022 ,